X

Trial Profile

Induction of Response and Remission of Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in Patients With Moderately to Severely Active Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary) ; Vedolizumab (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms COVET

Most Recent Events

21 May 2019 Status changed from recruiting to discontinued.
19 Oct 2018 Planned number of patients changed from 46 to 20.
12 Jul 2018 Planned primary completion date changed from 1 May 2019 to 1 Apr 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com